Related Experiment Video

Updated: Nov 8, 2025

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.1K

Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study

Minke Shi1, Jing Ma2, Meilin Feng2

  • 1Department of Thoracic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, China.

Cancer Genetics
|April 27, 2021
PubMed

Insights

Two novel MET exon 14 skipping mutations were identified in lung adenocarcinoma patients. These findings expand the understanding of MET alterations and potential targeted therapy options for lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MET exon 14 skipping (METex14) is a recognized driver in lung cancer.
  • MET tyrosine kinase inhibitors represent effective clinical treatments for MET-driven cancers.
  • Most known METex14 alterations involve canonical splicing or ubiquitination site mutations.

Observation:

  • Targeted next-generation sequencing (NGS) identified two previously undocumented METex14 variants in patients with lung adenocarcinoma.
  • Reverse transcription (RT)-based analyses confirmed that these novel mutations induce MET exon 14 skipping.

Findings:

  • Discovery of two new METex14 variants in lung adenocarcinoma.
  • Confirmation of these variants' ability to cause MET exon 14 skipping through RT-based assays.

Implications:

  • Broadens the spectrum of known MET alterations driving lung cancer.
  • Suggests potential for targeted therapy in patients with these newly identified MET mutations or similar analogs.
  • Highlights the importance of comprehensive genomic profiling for identifying actionable MET alterations.
Keywords:
MET alterationsMET exon 14 skipping analogNGSOncogenic driver

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K